Colchicine does not significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery, ...

At ACC 2026, retrospective results were presented demonstrating the possibility of using pharmacotherapies for patients after ...

Any cardiovascular protection from colchicine in heart attack survivors seemed to be debunked with a better-powered randomized trial, researchers found. Between acute MI patients randomized to ...

Get ready for a deep dive into colchicine and cardiovascular disease! We’ll examine the RCT data, and then pivot to discuss ...

Baseline serum metabolomic profiles may help predict gout flare risk at ULT initiation and identify patients less likely to respond adequately to colchicine prophylaxis.

WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...

Please provide your email address to receive an email when new articles are posted on . Historical use of colchicine, or its precursors, dates back several thousand years, with reports appearing in ...

NEW YORK — New insights into colchicine's disruption of the pathway that contributes to arterial inflammation and new clinical studies of the drug could pave the way toward greater use of the ...

Please provide your email address to receive an email when new articles are posted on . In patients referred for PCI after acute heart attack, colchicine did not improve heart-related outcomes vs.

AMSTERDAM -- Anti-inflammatory colchicine (Lodoco) given perioperatively around major non-cardiac thoracic surgery did not cut atrial fibrillation (Afib) or myocardial injury complications, the COP-AF ...

Colchicine is one of the oldest medicines with potent anti-inflammatory functions, widely used to treat rheumatic diseases such as gout, calcium pyrophosphate deposition disease (CPDD), and familial ...